|
74 Companies |
|
57 Products |
|
57 Products |
|
42 Mechanisms of Action |
|
2 Trials |
|
680 News |
|
| «12...234567891011121314» |
- Altabax (retapamulin) / GSK, Almirall
New P1 trial: Retapamulin Microdialysis Feasibility Study (clinicaltrials.gov) - Mar 14, 2013
P1, N=3, Not yet recruiting, Sponsor: GlaxoSmithKline
- |||||||||| Baxdela (delafloxacin) / Menarini, Melinta Therap
New P3 trial: Delafloxacin Versus Vancomycin and Aztreonam for the Treatment of Acute Bacterial Skin and Skin Structure Infections (clinicaltrials.gov) - Mar 13, 2013
P3, N=660, Recruiting, Sponsor: Melinta Therapeutics, Inc.
- ||| Trial completion: Study of the Use of Low Level Laser Light Therapy to Treat Toenail Fungus (clinicaltrials.gov) - Mar 12, 2013
P=N/A, N=105, Completed, Sponsor: Erchonia Corporation
Active, not recruiting --> Completed
- ||||||| Xepi (ozenoxacin) / Maruho, Cipher, Ferrer International
Trial completion: Efficacy and Safety of Ozenoxacin 1% Cream Versus Placebo in the Treatment of Patients With Impetigo (clinicaltrials.gov) - Mar 5, 2013
P3, N=465, Completed, Sponsor: Ferrer Internacional S.A.
Active, not recruiting --> Completed Recruiting --> Completed
- Trial initiation date: Clinical Study on Silk Sericin Wound Dressing for Split-thickness Skin Graft Donor Sites Treatment (clinicaltrials.gov) - Mar 4, 2013
P1/2, N=30, Recruiting, Sponsor: Chulalongkorn University
Recruiting --> Completed Initiation date: Apr 2012 --> Aug 2012
- |||| thimerosal (BTL-TML) / Beech Tree Labs
Trial completion: Safety and Efficacy Study of a New Treatment for Recurrent Symptoms of Oral Herpes Virus Infection (clinicaltrials.gov) - Mar 4, 2013
P1/2, N=171, Completed, Sponsor: Beech Tree Labs, Inc.
Initiation date: Apr 2012 --> Aug 2012 Active, not recruiting --> Completed
- ||||| Lytixar (LTX-109) / Lytix
New P2 trial: A Phase II Study to Evaluate the Efficacy and Safety of Two Doses of LTX-109 in Impetigo (clinicaltrials.gov) - Feb 28, 2013
P2, N=210, Completed, Sponsor: Lytix Biopharma AS
- Tembexa (brincidofovir oral) / SymBio Pharma
Trial initiation date: A Safety and Dose-Determining Study of CMX001 In Infants With Neonatal Herpes Simplex Virus (HSV) Infection Involving the Central Nervous System (CNS Disease) (clinicaltrials.gov) - Feb 28, 2013
P1/2, N=32, Not yet recruiting, Sponsor: University of Alabama at Birmingham
Active, not recruiting --> Completed Initiation date: Oct 2012 --> Jul 2013
- ||||| acyclovir / Generic mfg.
Trial initiation date, Head-to-Head: Non-inferiority Comparison of Efficacy and Safety of Penciclovir 10mg/g to Acyclovir 50mg/g in the Treatment of Recurrent Herpes Labialis (clinicaltrials.gov) - Feb 28, 2013
P3, N=76, Completed, Sponsor: EMS
Initiation date: Oct 2012 --> Jul 2013 Initiation date: Jun 2011 --> Feb 2012
- ||||||| acyclovir / Generic mfg.
Trial completion, Head-to-Head: Non-inferiority Comparison of Efficacy and Safety of Penciclovir 10mg/g to Acyclovir 50mg/g in the Treatment of Recurrent Herpes Labialis (clinicaltrials.gov) - Feb 28, 2013
P3, N=76, Completed, Sponsor: EMS
Initiation date: Jun 2011 --> Feb 2012 Not yet recruiting --> Completed
- Trial completion: Safety & Efficacy Study of HTU-520 in the Treatment of Distal Subungual Onychomycosis of the Toenail (clinicaltrials.gov) - Feb 27, 2013
P2, N=182, Completed, Sponsor: Hisamitsu Pharmaceutical Co., Inc.
Not yet recruiting --> Completed Active, not recruiting --> Completed
- Enrollment closed: Nebulized Amphotericin B Lipid Complex in Invasive Pulmonary Aspergillosis in Paediatric Patients With Acute Leukaemia (clinicaltrials.gov) - Feb 20, 2013
P2, N=30, Active, not recruiting, Sponsor: Fundaci
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- | valacyclovir / Generic mfg.
New P4 trial: Valacyclovir Augmentation for Cognitive and Functional Remediation in Schizophrenia (clinicaltrials.gov) - Feb 18, 2013
P4, N=156, Enrolling by invitation, Sponsor: University of Pittsburgh
- | Enrollment change: A Multicentre Randomised Controlled Trial Comparing Two Strategies for the Diagnosis of Invasive Aspergillosis in High-risk Haematology Patients (clinicaltrials.gov) - Feb 16, 2013
P3, N=240, Completed, Sponsor: Bayside Health
Recruiting --> Active, not recruiting N=600 --> 240
- | Trial completion: A Multicentre Randomised Controlled Trial Comparing Two Strategies for the Diagnosis of Invasive Aspergillosis in High-risk Haematology Patients (clinicaltrials.gov) - Feb 16, 2013
P3, N=240, Completed, Sponsor: Bayside Health
N=600 --> 240 Recruiting --> Completed
- ||||| acyclovir / Generic mfg.
Enrollment change: Open Label Safety Study of Xerese Cream in the Treatment of Recurrent Herpes Labialis in Children 6-11 Years Old (clinicaltrials.gov) - Feb 14, 2013
P3, N=51, Completed, Sponsor: Meda Pharmaceuticals
Recruiting --> Completed N=186 --> 51
- ||||||| acyclovir / Generic mfg.
Trial completion: Open Label Safety Study of Xerese Cream in the Treatment of Recurrent Herpes Labialis in Children 6-11 Years Old (clinicaltrials.gov) - Feb 14, 2013
P3, N=51, Completed, Sponsor: Meda Pharmaceuticals
N=186 --> 51 Recruiting --> Completed
- || gentamicin sulfate / Generic mfg.
New P3 trial: Phase 3 Study of Walter Reed (WR) 279,396 and Paromomycin Alone for the Treatment of Cutaneous Leishmaniasis in Panama (clinicaltrials.gov) - Feb 11, 2013
P3, N=300, Recruiting, Sponsor: U.S. Army Medical Research and Materiel Command
- | terbinafine (TDT 067) / Celtic
New P2 trial: TDT 067 Open Label Multi-Dose Onychomycosis Study (clinicaltrials.gov) - Feb 11, 2013
P2, N=27, Completed, Sponsor: Celtic Pharma Development Services
- Enrollment open: CL Detect™: Evaluation of a Rapid Diagnostic Device, CL Detect, for the Diagnosis of Cutaneous Leishmaniasis in Tunisia (clinicaltrials.gov) - Feb 11, 2013
P=N/A, N=167, Recruiting, Sponsor: U.S. Army Medical Research and Materiel Command
Recruiting --> Completed Not yet recruiting --> Recruiting
- ||||| tigecycline / Generic mfg.
New P4 trial: TIGER: Tygacil Drug Use Investigation (clinicaltrials.gov) - Feb 10, 2013
P4, N=100, Enrolling by invitation, Sponsor: Pfizer
- Enrollment change: The Underlying Mechanisms For S. Aureus Infection And Colonization Of Skin in People With Atopic Dermatitis With And Without Eczema Herpeticum (MRSA) (clinicaltrials.gov) - Feb 4, 2013
P=N/A, N=65, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting --> Recruiting N=130 --> 65
- New P2/3 trial: Oral Zinc Gluconate as Treatment for Recalcitrant Cutaneous Warts: A Randomized, Double-blind, Placebo-controlled Trial (clinicaltrials.gov) - Jan 31, 2013
P2/3, N=28, Completed, Sponsor: Philippine Dermatological Society
- ||| ceftaroline fosamil / Generic mfg.
Trial completion, Gram positive, Gram negative: CERBERUS: Multicenter Study of Antimicrobial Resistance of Gram-positive and Gram-negative Clinical Strains to Ceftaroline and Other Antimicrobials in Russia (clinicaltrials.gov) - Jan 31, 2013
P=N/A, N=3000, Completed, Sponsor: AstraZeneca
N=130 --> 65 Recruiting --> Completed
- ||| HSV vaccine (GEN-003) / Genocea, Shionogi
Enrollment closed: Safety and Immunogenicity Study of Therapeutic HSV-2 Vaccine (clinicaltrials.gov) - Jan 27, 2013
P1/2, N=150, Active, not recruiting, Sponsor: Genocea Biosciences, Inc.
Recruiting --> Completed Recruiting --> Active, not recruiting
- ||||| Enrollment change: Topical Antifungal Treatment for Tinea Cruris (clinicaltrials.gov) - Jan 21, 2013
P3, N=483, Completed, Sponsor: Medicis Global Service Corporation
Recruiting --> Active, not recruiting N=390 --> 483
- Enrollment open: Rapid Diagnostic Tests and Clinical/Laboratory Predictors of Tropical Diseases In Patients With Persistent Fever in Cambodia, Nepal, Democratic Republic of the Congo and Sudan (NIDIAG-Fever) (clinicaltrials.gov) - Jan 21, 2013
P=N/A, N=2170, Recruiting, Sponsor: University Hospital, Geneva
N=390 --> 483 Not yet recruiting --> Recruiting
- ||||||| Trial completion: Topical Antifungal Treatment for Tinea Pedis (clinicaltrials.gov) - Jan 21, 2013
P3, N=322, Completed, Sponsor: Medicis Global Service Corporation
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- ||||||| Trial completion: Topical Antifungal Treatment for Tinea Pedis (clinicaltrials.gov) - Jan 21, 2013
P3, N=321, Completed, Sponsor: Medicis Global Service Corporation
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||||||| Trial completion: Safety of a Topical Antifungal Treatment for Tinea Cruris, Tinea Pedis and Tinea Corporis (clinicaltrials.gov) - Jan 21, 2013
P3, N=604, Completed, Sponsor: Tinea Pharmaceuticals
Active, not recruiting --> Completed Recruiting --> Completed
- ||||||| Trial completion: Topical Antifungal Treatment for Tinea Cruris (clinicaltrials.gov) - Jan 21, 2013
P3, N=483, Completed, Sponsor: Medicis Global Service Corporation
Recruiting --> Completed Active, not recruiting --> Completed
- Cubicin (daptomycin) / Merck (MSD)
Enrollment open: Evaluation of Daptomycin for the Emergency Department Treatment of Complicated Skin and Skin Structure Infections (clinicaltrials.gov) - Jan 15, 2013
P4, N=100, Recruiting, Sponsor: University of Cincinnati
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- amphotericin b liposome / Generic mfg.
Enrollment change: LVBrasil: Efficacy and Safety Study of Drugs for Treatment of Visceral Leishmaniasis in Brazil (clinicaltrials.gov) - Jan 13, 2013
P4, N=423, Recruiting, Sponsor: University of Brasilia
Not yet recruiting --> Recruiting N=660 --> 423
- Trial completion, Preclinical, Diagnostic assay: The Efficacy of Two Potential Diagnostic Assays for Herpes Simplex Keratitis (HSK) (clinicaltrials.gov) - Jan 13, 2013
P1, N=50, Completed, Sponsor: University of Ulster
N=660 --> 423 Recruiting --> Completed
- || Enrollment change: Typing of Human Papilloma Virus (HPV) From Female Genital Warts (clinicaltrials.gov) - Jan 12, 2013
P=N/A, N=156, Completed, Sponsor: University of Cape Town
Recruiting --> Completed N=130 --> 156
- ||| Trial completion: Typing of Human Papilloma Virus (HPV) From Female Genital Warts (clinicaltrials.gov) - Jan 12, 2013
P=N/A, N=156, Completed, Sponsor: University of Cape Town
N=130 --> 156 Recruiting --> Completed
- Cubicin (daptomycin) / Merck (MSD)
Trial withdrawal: Clinical Usefulness of Mic/Breakpoint Ratio and Penetration in Tissues. A Prospective Study of Clinical Validation (clinicaltrials.gov) - Dec 27, 2012
P=N/A, N=0, Withdrawn, Sponsor: Federico II University
Recruiting --> Completed Recruiting --> Withdrawn
- Cubicin (daptomycin) / Merck (MSD)
Enrollment change: Clinical Usefulness of Mic/Breakpoint Ratio and Penetration in Tissues. A Prospective Study of Clinical Validation (clinicaltrials.gov) - Dec 27, 2012
P=N/A, N=0, Withdrawn, Sponsor: Federico II University
Recruiting --> Withdrawn N=100 --> 0
- | minocycline / Generic mfg.
New P1 trial: Bioequivalence Minocycline Bioequivalence (clinicaltrials.gov) - Dec 20, 2012
P1, N=25, Completed, Sponsor: GlaxoSmithKline
- Kenketsu Glovenin-I (normal human immunoglobulin IV) / Takeda
Enrollment open: Phase III Clinical Trial of NPB-01 in Patients With Stevens-Johnson Syndrome/ Toxic Epidermal Necrolysis Unresponsive to Corticosteroids. (clinicaltrials.gov) - Dec 17, 2012
P3, N=10, Recruiting, Sponsor: Nihon Pharmaceutical Co., Ltd
N=100 --> 0 Not yet recruiting --> Recruiting
- New P1 trial: LEISH-F3 + GLA-SE and the LEISH-F3 + MPL-SE Vaccine (clinicaltrials.gov) - Dec 13, 2012
P1, N=48, Active, not recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
- Enrollment open: Soft Tissue Ultrasound of Infections (clinicaltrials.gov) - Dec 2, 2012
P1, N=15, Recruiting, Sponsor: Rhode Island Hospital
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- |||| Trial completion: A Complicated Skin and Soft-tissue Infection Patient Registry (clinicaltrials.gov) - Nov 28, 2012
P4, N=1081, Completed, Sponsor: Ortho-McNeil Janssen Scientific Affairs, LLC
Not yet recruiting --> Recruiting Recruiting --> Completed
- |||| acyclovir / Generic mfg.
Trial completion: An Exploratory Study to Investigate the Inflammatory Response During a Cold Sore Episode (clinicaltrials.gov) - Nov 27, 2012
P2, N=60, Completed, Sponsor: GlaxoSmithKline
Recruiting --> Completed Not yet recruiting --> Completed
- gentamicin sulfate / Generic mfg.
Trial suspension: WR 279,396 Open Label Treatment Protocol in Tunisia (clinicaltrials.gov) - Nov 26, 2012
P2, N=120, Suspended, Sponsor: U.S. Army Medical Research and Materiel Command
Not yet recruiting --> Completed Recruiting --> Suspended
- Enrollment open: Human Papillomavirus (HPV) Types Present in External Genital Warts (EGW) in the Argentinean Population (clinicaltrials.gov) - Nov 13, 2012
P=N/A, N=150, Recruiting, Sponsor: University of Buenos Aires
Recruiting --> Suspended Not yet recruiting --> Recruiting
- amoxicillin / Generic mfg.
Trial withdrawal: The Use of Prophylactic Antibiotics in Isolated Blowout Fractures (clinicaltrials.gov) - Nov 7, 2012
P=N/A, N=0, Withdrawn, Sponsor: University of Arkansas
Not yet recruiting --> Recruiting Recruiting --> Withdrawn
- amoxicillin / Generic mfg.
Enrollment change: The Use of Prophylactic Antibiotics in Isolated Blowout Fractures (clinicaltrials.gov) - Nov 7, 2012
P=N/A, N=0, Withdrawn, Sponsor: University of Arkansas
Recruiting --> Withdrawn N=100 --> 0
- ||||||| Zeven (dalbavancin) / RaQualia, AbbVie
Trial completion: Efficacy and Safety of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections (clinicaltrials.gov) - Nov 4, 2012
P3, N=739, Completed, Sponsor: Durata Therapeutics, Inc.
N=100 --> 0 Recruiting --> Completed
- |||| Trial completion: Efficacy and Safety of Two Treatment Regimens of Topical MOB015 in Adults With Distal Subungual Onychomycosis (clinicaltrials.gov) - Oct 23, 2012
P2, N=250, Completed, Sponsor: Moberg Derma AB
Recruiting --> Completed Active, not recruiting --> Completed